Pharmaceutical In Morningstar’s recent ESG Industry Landscape Report: Biopharma, its analysts found that large drug manufacturers face moderate environmental, social and governance (ESG) risk exposure but have limited materiality to valuation. More specifically, access to basic services, product governance, and business ethics are the three most material ESG risks to pharma and biotech companies. 2 February 2023